Results 231 to 240 of about 1,181,987 (277)

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study. [PDF]

Int J Retina Vitreous
Kanadani T, Rabelo N, Takahashi D, Magalhães L, Farah M.   +4 more
europepmc   +1 more source

BMI‐1 modulation and trafficking during M phase in diffuse intrinsic pontine glioma

FEBS Open Bio, EarlyView.
The schematic illustrates BMI‐1 phosphorylation during M phase, which triggers its translocation from the nucleus to the cytoplasm. In cycling cells, BMI‐1 functions within the PRC1 complex to mediate H2A K119 monoubiquitination. Following PTC596‐induced M phase arrest, phosphorylated BMI‐1 dissociates from PRC1 and is exported to the cytoplasm via its
Banlanjo Umaru, Deepak Kumar Mishra, Shiva Senthil Kumar, Hao‐Han Pang, Brendan Devine, Komal Khan, Rachid Drissi   +6 more
wiley   +1 more source

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

FEBS Open Bio, EarlyView.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi, Zainab Quraishi, Shima Khezri Azizi Far, Madaleine Ward, Aidan Conway, Reem Abdulredha, Eman Mshari, Yousif A. Shamsaldeen   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Treat and extend regimen for diabetic macular oedema—a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
Various treatment regimens are currently practiced in the treatment of CI-DMO (centre-involving diabetic macular oedema). In recent years, there has been a growing body of evidence supporting a treat and extend (T&E) regimen for DMO which offers the promise of comparable visual and anatomical outcomes while reducing injection burden. This meta-analysis
Sheng Yang Lim, Wendy Meihua Wong, Ivan Seah, Hwei Wuen Chan, Xinyi Su, Gopal Lingam, Yew Sen Yuen   +6 more
openaire   +2 more sources

OCT-angiography follow-up of choroidal neovascularization treated with treat-and- extend aflibercept regimen to avoid over-treatment

European Journal of Ophthalmology, 2022
Purpose To propose optical coherence tomography angiography (OCT-A) for the follow-up of neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend (T&E) aflibercept regimen to avoid overtreatment. Methods Retrospective, cohort, pilot study.
Claudio Furino, Valeria Albano, Michela Mangione, Roberta Galati, Maria D’Addario, Michele Reibaldi, Francesco Boscia, Giovanni Alessio   +7 more
openaire   +4 more sources

TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

Retina, 2016
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve retinal angiomatous proliferation (RAP) and development of retinal pigment epithelium (RPE) atrophy.We retrospectively studied 17 treated eyes with RAP and 13 untreated fellow eyes.
Hidetaka, Matsumoto, Taku, Sato, Masahiro, Morimoto, Ryo, Mukai, Maki, Takahashi, Takashi, Hiroe, Kensuke, Ehara, Mayuko, Takayama, Kensuke, Mimura, Shoji, Kishi   +9 more
openaire   +2 more sources

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +2 more sources

TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Retina, 2017
To investigate the efficacy of a treat-and-extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV).We retrospectively reviewed the medical records of 29 patients with PCV, who had been treated with a TER for 1 year. The primary outcome was the proportion of eyes that did not lose ≥3 best-corrected visual acuity (BCVA ...
Kang Yeun, Pak, Sung Who, Park, Ik Soo, Byon, Ji Eun, Lee   +3 more
openaire   +2 more sources

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Blood, 2023
Background: Covalent Bruton tyrosine kinase inhibitor (cBTKi) is a standard treatment for chronic lymphocytic leukemia (CLL). Understanding of acquired resistance to cBTKi therapy has largely come from data on patients (pts) treated with the first-in-class cBTKi ibrutinib.
Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner   +9 more
openaire   +1 more source

Treat and extend versus PRN in diabetic retinopathy

Acta Ophthalmologica, 2016
SummaryVascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of the neo‐vascular age related macular degeneration (nAMD) and the ischemic retinal microangiopathies. Targeting VEGF in retinal diseases became an effective therapeutic option.To optimize the benefit of risk ratio and cost effectiveness of anti‐VEGF agents, a number
openaire   +1 more source